KUP-101A / Kupando - LARVOL DELTA

Natera and Kupando Therapeutics Partner for Phase I Trial of KUP-101 in Advanced Skin Cancers (The Dermatology Digest) - "Under the agreement, Natera’s Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando’s clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial ctDNA dynamics as part of treatment response monitoring. "

Licensing / partnership • New P1 trial • Cutaneous Melanoma • Skin Cancer

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Kupando GmbH | Initiation date: Apr 2026 ➔ Jul 2026

First-in-human • Trial initiation date • Basal Cell Carcinoma • Cutaneous Melanoma • Melanoma • Merkel Cell Carcinoma • Mucosal Melanoma • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer